Biotech Hangout
Episode 50
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
This week, Paul Hastings, Chief Executive Officer and President of Nkarta Therapeutics and Chair of the Biotechnology Innovation Organization (BIO), joins Biotech Hangout hosts Daphne Zohar, Josh Schimmer, Rob Perez and Dawn Bell. The group discusses the latest biotech industry consolidations and dissolutions and Big Pharma’s looming patent cliff. They touch on controversies surrounding Vertex’s latest drug pricing, the abortion pill ban and pending implications for the FDA, industry diversity and Vivek Ramaswamy’s resignation from Roivant’s Board of Directors as he prepares to pursue his U.S. presidential campaign.